Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT
Salyka Sengsayadeth,
Bipin N. Savani,
Didier Blaise,
Florent Malard,
Arnon Nagler,
Mohamad Mohty
Affiliations
Salyka Sengsayadeth
Section of Hematology and Stem Cell Transplant, Vanderbilt University Medical Center, Nashville, TN, USA
Bipin N. Savani
Section of Hematology and Stem Cell Transplant, Vanderbilt University Medical Center, Nashville, TN, USA;Acute Leukemia Working Party of the EBMT, Marseille, France
Didier Blaise
Programme de Transplantation & Therapie Cellulaire - Centre de Recherche en Cancérologie de Marseille - Institut Paoli Calmettes, Marseille, France
Florent Malard
Department of Haematology, Saint Antoine Hospital, Paris, France;INSERM UMR 938, Paris, France;Université Pierre et Marie Curie, Paris, France
Arnon Nagler
Acute Leukemia Working Party of the EBMT, Marseille, France;Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel;EBMT Paris Study Office/CEREST-TC, Paris, France
Mohamad Mohty
Department of Haematology, Saint Antoine Hospital, Paris, France;INSERM UMR 938, Paris, France;Université Pierre et Marie Curie, Paris, France;EBMT Paris Study Office/CEREST-TC, Paris, France
Acute myeloid leukemia is the most common indication for an allogeneic hematopoietic cell transplant. The introduction of reduced intensity conditioning has expanded the recipient pool for transplantation, which has importantly made transplant an option for the more commonly affected older age groups. Reduced intensity conditioning allogeneic transplantation is currently the standard of care for patients with intermediate or high-risk acute myeloid leukemia and is now most often employed in older patients and those with medical comorbidities. Despite being curative for a significant proportion of patients, post-transplant relapse remains a challenge in the reduced intensity conditioning setting. Herein we discuss the studies that demonstrate the feasibility of reduced intensity conditioning allogeneic transplants, compare the outcomes of reduced intensity conditioning versus chemotherapy and conventional myeloablative conditioning regimens, describe the optimal donor and stem cell source, and consider the impact of post-remission consolidation, comorbidities, center experience, and more intensive (reduced toxicity conditioning) regimens on outcomes. Additionally, we discuss the need for further prospective studies to optimize transplant outcomes.